Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled clinical trial.

Fiche publication

Date publication

juillet 2025

Journal

Journal of hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DI MARTINO Vincent , Pr HOCQUET Didier

Tous les auteurs :
Thévenot T, Elkrief L, Bureau C, Bardou-Jacquet E, Rosa I, Nguyen-Khac E, Oberti F, Pitta A, Mallet M, Lebossé F, Louvet A, Meunier L, Nahon P, Ollivier-Hourmand I, Anty R, Francoz C, Riachi G, Meunier A, Cervoni JP, Tio G, Muller A, Curé-Martin A, Ladeira R, Clairet AL, Hocquet D, Di Martino V, Weil D, Desmarets M, ,,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40653111

Résumé

Evidence for primary prophylaxis of spontaneous bacterial peritonitis (SBP) is weak and the selection of quinolone-resistant bacteria is currently of concern. Here we present results from a randomized, double-blind, placebo (PBO)-controlled trial to assess whether rifaximin (RFX) has a beneficial effect on 12-month survival in patients with severe cirrhosis and ascites.